Aligos Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $36 price target The company’s lead asset, ALG-000184, is a potent small-molecule core assembly modulator in development for chronic hepatitis B, the analyst tells investors in a research note. The firm says that in Phase 1, ALG-000184 demonstrated potential best-in-class antiviral activity. It believes Aligos “represents a compelling opportunity at a very attractive entry point.”